Trials / Completed
CompletedNCT04631445
Study Evaluating the Ketogenic Diet in Patients With Metastatic Pancreatic Cancer
Randomized Phase II Trial of Two Different Nutritional Approaches for Patients Receiving Treatment for Their Advanced Pancreatic Cancer
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Translational Drug Development · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the effects of the ketogenic diet in patients with metastatic pancreatic cancer while receiving chemotherapy.
Detailed description
A randomized, phase II trial designed to evaluate the progression free survival in patients with metastatic pancreatic cancer on triplet therapy (nab-paclitaxel + gemcitabine + cisplatin) while on ketogenic diet or non-ketogenic diet. This study also aims to compare the changes in serum metabolites and quality of life between the two arms.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Ketogenic Diet | Ketogenic diet (KD) will consist of macros: dietary carbohydrates restricted to \< 30 g/day; daily protein intake will be targeted to 1.5 g/kg/day (targeted to ideal body weight). |
Timeline
- Start date
- 2020-12-02
- Primary completion
- 2025-02-01
- Completion
- 2025-02-01
- First posted
- 2020-11-17
- Last updated
- 2025-02-21
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT04631445. Inclusion in this directory is not an endorsement.